|
1
|
Magnani L, Brunelle M, Gévry N and Lupien
M: Chromatin landscape and endocrine response in breast cancer.
Epigenomics. 4:675–683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheang MC, van de Rijn M and Nielsen TO:
Gene expression profiling of breast cancer. Annu Rev Pathol.
3:67–97. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Normanno N, Di Maio M, De Maio E, De Luca
A, de Matteis A, Giordano A and Perrone F; NCI-Naple Breast Cancer
Group, : Mechanisms of endocrine resistance and novel therapeutic
strategies in breast cancer. Endocr Relat Cancer. 12:721–747. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cardoso F, Costa A, Senkus E, Aapro M,
André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso
MJ, et al: 3rd ESO-ESMO international consensus guidelines for
Advanced Breast Cancer (ABC 3). Breast. 31:244–259. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodríguez-Paredes M and Esteller M: Cancer
epigenetics reaches mainstream oncology. Nat Med. 17:330–339. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jones PA: Functions of DNA methylation:
Islands, start sites, gene bodies and beyond. Nat Rev Genet.
13:484–492. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bannister AJ and Kouzarides T: Regulation
of chromatin by histone modifications. Cell Res. 21:381–395. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zentner GE and Henikoff S: Regulation of
nucleosome dynamics by histone modifications. Nat Struct Mol Biol.
20:259–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amorim M, Salta S, Henrique R and Jerónimo
C: Decoding the usefulness of non-coding RNAs as breast cancer
markers. J Transl Med. 14:2652016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kung JT, Colognori D and Lee JT: Long
noncoding RNAs: Past, present, and future. Genetics. 193:651–669.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huntzinger E and Izaurralde E: Gene
silencing by microRNAs: Contributions of translational repression
and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sharma D, Blum J, Yang X, Beaulieu N,
Macleod AR and Davidson NE: Release of methyl CpG binding proteins
and histone deacetylase 1 from the estrogen receptor α (ER)
promoter upon reactivation in ER-negative human breast cancer
cells. Mol Endocrinol. 19:1740–1751. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heyn H and Esteller M: DNA methylation
profiling in the clinic: Applications and challenges. Nat Rev
Genet. 13:679–692. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jerónimo C and Henrique R: Epigenetic
biomarkers in urological tumors: A systematic review. Cancer Lett.
342:264–274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Costa-Pinheiro P, Montezuma D, Henrique R
and Jerónimo C: Diagnostic and prognostic epigenetic biomarkers in
cancer. Epigenomics. 7:1003–1015. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Widschwendter M, Siegmund KD, Müller HM,
Fiegl H, Marth C, Müller-Holzner E, Jones PA and Laird PW:
Association of breast cancer DNA methylation profiles with hormone
receptor status and response to tamoxifen. Cancer Res.
64:3807–3813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan M, Yan PS, Hartman-Frey C, Chen L,
Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al:
Diverse gene expression and DNA methylation profiles correlate with
differential adaptation of breast cancer cells to the antiestrogens
tamoxifen and fulvestrant. Cancer Res. 66:11954–11966. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stone A, Zotenko E, Locke WJ, Korbie D,
Millar EK, Pidsley R, Stirzaker C, Graham P, Trau M, Musgrove EA,
et al: DNA methylation of oestrogen-regulated enhancers defines
endocrine sensitivity in breast cancer. Nat Commun. 6:77582015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Williams KE, Anderton DL, Lee MP,
Pentecost BT and Arcaro KF: High-density array analysis of DNA
methylation in Tamoxifen-resistant breast cancer cell lines.
Epigenetics. 9:297–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maier S, Nimmrich I, Koenig T,
Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen
C, Mueller V, Nährig J, et al: European Organisation for Research
and Treatment of Cancer (EORTC) PathoBiology group: DNA-methylation
of the homeodomain transcription factor PITX2 reliably predicts
risk of distant disease recurrence in tamoxifen-treated,
node-negative breast cancer patients: Technical and clinical
validation in a multi-centre setting in collaboration with the
European Organisation for Research and Treatment of Cancer (EORTC)
PathoBiology group. Eur J Cancer. 43:1679–1686. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harbeck N, Nimmrich I, Hartmann A, Ross
JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O,
Margossian A, et al: Multicenter study using paraffin-embedded
tumor tissue testing PITX2 DNA methylation as a marker for
outcome prediction in tamoxifen-treated, node-negative breast
cancer patients. J Clin Oncol. 26:5036–5042. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miller TE, Ghoshal K, Ramaswamy B, Roy S,
Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222
confers tamoxifen resistance in breast cancer by targeting
p27Kip1. J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao JJ, Lin J, Yang H, Kong W, He L, Ma
X, Coppola D and Cheng JQ: MicroRNA-221/222 negatively regulates
estrogen receptor α and is associated with tamoxifen resistance in
breast cancer. J Biol Chem. 283:31079–31086. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rao X, Di Leva G, Li M, Fang F, Devlin C,
Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP:
MicroRNA-221/222 confers breast cancer fulvestrant resistance by
regulating multiple signaling pathways. Oncogene. 30:1082–1097.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cittelly DM, Das PM, Spoelstra NS,
Edgerton SM, Richer JK, Thor AD and Jones FE: Downregulation of
miR-342 is associated with tamoxifen resistant breast tumors. Mol
Cancer. 9:3172010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R
and Tang JH: miR-342 is associated with estrogen receptor-α
expression and response to tamoxifen in breast cancer. Exp Ther
Med. 5:813–818. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ward A, Shukla K, Balwierz A, Soons Z,
König R, Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir
conferring tamoxifen resistance by targeting a network of
tumour-suppressor genes in ER+ breast cancer. J Pathol.
233:368–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
ClinicalTrials.gov: MIRNA Profiling of
Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant
Treatment for Locally Advanced & Inflammatory Breast Cancer.
ClinicalTrials.gov2016. https://clinicaltrials.gov/ct2/show/NCT01231386
|
|
31
|
ClinicalTrials.gov: Circulating miRNAs.
ICORG 10–11, V2. ClinicalTrials.gov2017. https://clinicaltrials.gov/ct2/show/NCT01722851
|
|
32
|
ClinicalTrials.gov: Circulating miRNAs as
Biomarkers of Hormone Sensitivity in Breast Cancer (MIRHO).
ClinicalTrials.gov. 2014, https://clinicaltrials.gov/ct2/show/NCT01612871
|
|
33
|
Meijer D, van Agthoven T, Bosma PT, Nooter
K and Dorssers LC: Functional screen for genes responsible for
tamoxifen resistance in human breast cancer cells. Mol Cancer Res.
4:379–386. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Godinho MF, Sieuwerts AM, Look MP, Meijer
D, Foekens JA, Dorssers LC and Van Agthoven T: Relevance of BCAR4
in tamoxifen resistance and tumour aggressiveness of human breast
cancer. Br J Cancer. 103:1284–1291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Niknafs YS, Han S, Ma T, Speers C, Zhang
C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, et al:
The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1
in breast cancer progression. Nat Commun. 7:127912016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Magnani L, Stoeck A, Zhang X, Lánczky A,
Mirabella AC, Wang TL, Gyorffy B and Lupien M: Genome-wide
reprogramming of the chromatin landscape underlies endocrine
therapy resistance in breast cancer. Proc Natl Acad Sci USA.
110:E1490–E1499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Duan Z, Nugent Z, Zou JX, Borowsky
AD, Zhang Y, Tepper CG, Li JJ, Fiehn O, Xu J, et al: Reprogramming
metabolism by histone methyltransferase NSD2 drives endocrine
resistance via coordinated activation of pentose phosphate pathway
enzymes. Cancer Lett. 378:69–79. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jansen MP, Knijnenburg T, Reijm EA, Simon
I, Kerkhoven R, Droog M, Velds A, van Laere S, Dirix L, Alexi X, et
al: Hallmarks of aromatase inhibitor drug resistance revealed by
epigenetic profiling in breast cancer. Cancer Res. 73:6632–6641.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Légaré S and Basik M: Minireview: The link
between ERα corepressors and histone deacetylases in tamoxifen
resistance in breast cancer. Mol Endocrinol. 30:965–976. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Munster PN, Thurn KT, Thomas S, Raha P,
Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M,
et al: A phase II study of the histone deacetylase inhibitor
vorinostat combined with tamoxifen for the treatment of patients
with hormone therapy-resistant breast cancer. Br J Cancer.
104:1828–1835. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yardley DA, Ismail-Khan RR, Melichar B,
Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee
MJ and Trepel JB: Randomized phase II, double-blind,
placebo-controlled study of exemestane with or without entinostat
in postmenopausal women with locally recurrent or metastatic
estrogen receptor-positive breast cancer progressing on treatment
with a nonsteroidal aromatase inhibitor. J Clin Oncol.
31:2128–2135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Raha P, Thomas S, Thurn KT, Park J and
Munster PN: Combined histone deacetylase inhibition and tamoxifen
induces apoptosis in tamoxifen-resistant breast cancer models, by
reversing Bcl-2 overexpression. Breast Cancer Res. 17:262015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gévry N, Hardy S, Jacques P-É, Laflamme L,
Svotelis A, Robert F and Gaudreau L: Histone H2A.Z is essential for
estrogen receptor signaling. Genes Dev. 23:1522–1533. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Svotelis A, Gévry N, Grondin G and
Gaudreau L: H2A.Z overexpression promotes cellular proliferation of
breast cancer cells. Cell Cycle. 9:364–370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nayak SR, Harrington E, Boone D, Hartmaier
R, Chen J, Pathiraja TN, Cooper KL, Fine JL, Sanfilippo J, Davidson
NE, et al: A role for histone H2B variants in endocrine-resistant
breast cancer. Horm Cancer. 6:214–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Magnani L, Ballantyne EB, Zhang X and
Lupien M: PBX1 genomic pioneer function drives ERα signaling
underlying progression in breast cancer. PLoS Genet.
7:e10023682011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH,
Lee KY, Ahn SG, Yoon JH and Kang KW: Role of PTEN promoter
methylation in tamoxifen-resistant breast cancer cells. Breast
Cancer Res Treat. 130:73–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hiken JF, McDonald JI, Decker KF, Sanchez
C, Hoog J, VanderKraats ND, Jung KL, Akinhanmi M, Rois LE, Ellis
MJ, et al: Epigenetic activation of the prostaglandin receptor EP4
promotes resistance to endocrine therapy for breast cancer.
Oncogene. 36:2319–2327. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Iorns E, Turner NC, Elliott R, Syed N,
Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ and Ashworth A:
Identification of CDK10 as an important determinant of resistance
to endocrine therapy for breast cancer. Cancer Cell. 13:91–104.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pathiraja TN, Nayak SR, Xi Y, Jiang S,
Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, et al:
Epigenetic reprogramming of HOXC10 in endocrine-resistant
breast cancer. Sci Transl Med. 6:229ra412014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang Y, Zhang B, Fang J and Cao X:
Hypomethylation of DNA-binding inhibitor 4 serves as a potential
biomarker in distinguishing acquired tamoxifen-refractory breast
cancer. Int J Clin Exp Pathol. 8:9500–9505. 2015.PubMed/NCBI
|
|
52
|
Kim SJ, Kang HS, Jung SY, Min SY, Lee S,
Kim SW, Kwon Y, Lee KS, Shin KH and Ro J: Methylation patterns of
genes coding for drug-metabolizing enzymes in tamoxifen-resistant
breast cancer tissues. J Mol Med. 88:1123–1131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nimmrich I, Sieuwerts AM, Meijer-van
Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T,
Hartmann O, Kluth A, Dietrich D, et al: DNA hypermethylation of
PITX2 is a marker of poor prognosis in untreated lymph
node-negative hormone receptor-positive breast cancer patients.
Breast Cancer Res Treat. 111:429–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pathiraja TN, Shetty PB, Jelinek J, He R,
Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP and Oesterreich
S: Progesterone receptor isoform-specific promoter methylation:
Association of PRA promoter methylation with worse outcome
in breast cancer patients. Clin Cancer Res. 17:4177–4186. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Martens JW, Nimmrich I, Koenig T, Look MP,
Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM,
Portengen H, et al: Association of DNA methylation of phosphoserine
aminotransferase with response to endocrine therapy in patients
with recurrent breast cancer. Cancer Res. 65:4101–4117. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ward A, Balwierz A, Zhang JD, Küblbeck M,
Pawitan Y, Hielscher T, Wiemann S and Sahin Ö: Re-expression of
microRNA-375 reverses both tamoxifen resistance and accompanying
EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cui J, Yang Y, Li H, Leng Y, Qian K, Huang
Q, Zhang C, Lu Z, Chen J, Sun T, et al: MiR-873 regulates ERα
transcriptional activity and tamoxifen resistance via targeting
CDK3 in breast cancer cells. Oncogene. 34:3895–3907. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lü M, Ding K, Zhang G, Yin M, Yao G, Tian
H, Lian J, Liu L, Liang M, Zhu T, et al: MicroRNA-320a sensitizes
tamoxifen-resistant breast cancer cells to tamoxifen by targeting
ARPP-19 and ERRγ. Sci Rep. 4:87352015. View Article : Google Scholar
|
|
59
|
Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M,
Recker RR, Gatalica Z, Wang Z and Xiao GG: let-7 microRNAs
induce tamoxifen sensitivity by downregulation of estrogen receptor
α signaling in breast cancer. Mol Med. 17:1233–1241. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bergamaschi A and Katzenellenbogen BS:
Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes
breast cancer cell survival and endocrine resistance. Oncogene.
31:39–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yu Z, Xu Z, Disante G, Wright J, Wang M,
Li Y, Zhao Q, Ren T, Ju X, Gutman E, et al: miR-17/20 sensitization
of breast cancer cells to chemotherapy-induced apoptosis requires
Akt1. Oncotarget. 5:1083–1090. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen MJ, Cheng YM, Chen CC, Chen YC and
Shen CJ: MiR-148a and miR-152 reduce tamoxifen resistance in
ER+ breast cancer via downregulating ALCAM. Biochem
Biophys Res Commun. 483:840–846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Manavalan TT, Teng Y, Litchfield LM,
Muluhngwi P, Al-Rayyan N and Klinge CM: Reduced expression of
miR-200 family members contributes to antiestrogen resistance in
LY2 human breast cancer cells. PLoS One. 8:e623342013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cittelly DM, Das PM, Salvo VA, Fonseca JP,
Burow ME and Jones FE: Oncogenic HER2{Delta}16 suppresses
miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of
breast tumors. Carcinogenesis. 31:2049–2057. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jansen MP, Reijm EA, Sieuwerts AM,
Ruigrok-Ritstier K, Look MP, Rodríguez-González FG, Heine AA,
Martens JW, Sleijfer S, Foekens JA, et al: High miR-26a and low
CDC2 levels associate with decreased EZH2 expression and with
favorable outcome on tamoxifen in metastatic breast cancer. Breast
Cancer Res Treat. 133:937–947. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Rodríguez-González FG, Sieuwerts AM, Smid
M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens
JW and Foekens JA: MicroRNA-30c expression level is an independent
predictor of clinical benefit of endocrine therapy in advanced
estrogen receptor positive breast cancer. Breast Cancer Res Treat.
127:43–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hoppe R, Achinger-Kawecka J, Winter S,
Fritz P, Lo WY, Schroth W and Brauch H: Increased expression of
miR-126 and miR-10a predict prolonged relapse-free time of primary
oestrogen receptor-positive breast cancer following tamoxifen
treatment. Eur J Cancer. 49:3598–3608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ahmad A, Ginnebaugh KR, Yin S,
Bollig-Fischer A, Reddy KB and Sarkar FH: Functional role of
miR-10b in tamoxifen resistance of ER-positive breast cancer cells
through downregulation of HDAC4. BMC Cancer. 15:5402015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y,
Li H, Zhu X, Yao L and Zhang J: Exosomal miR-221/222 enhances
tamoxifen resistance in recipient ER-positive breast cancer cells.
Breast Cancer Res Treat. 147:423–431. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shen R, Wang Y, Wang CX, Yin M, Liu HL,
Chen JP, Han JQ and Wang WB: MiRNA-155 mediates TAM resistance by
modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J
Transl Res. 7:2115–2126. 2015.PubMed/NCBI
|
|
71
|
Rothé F, Ignatiadis M, Chaboteaux C,
Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H,
Desmedt C, Harris AL, et al: Global microRNA expression profiling
identifies MiR-210 associated with tumor proliferation, invasion
and poor clinical outcome in breast cancer. PLoS One. 6:e209802011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Shibahara Y, Miki Y, Onodera Y, Hata S,
Chan MS, Yiu CC, Loo TY, Nakamura Y, Akahira J, Ishida T, et al:
Aromatase inhibitor treatment of breast cancer cells increases the
expression of let-7f, a microRNA targeting CYP19A1. J
Pathol. 227:357–366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bailey ST, Westerling T and Brown M: Loss
of estrogen-regulated microRNA expression increases HER2 signaling
and is prognostic of poor outcome in luminal breast cancer. Cancer
Res. 75:436–445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Masri S, Liu Z, Phung S, Wang E, Yuan YC
and Chen S: The role of microRNA-128a in regulating TGFbeta
signaling in letrozole-resistant breast cancer cells. Breast Cancer
Res Treat. 124:89–99. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hayes EL and Lewis-Wambi JS: Mechanisms of
endocrine resistance in breast cancer: An overview of the proposed
roles of noncoding RNA. Breast Cancer Res. 17:402015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang Z, Yamashita H, Toyama T, Sugiura H,
Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S and Iwase H: HDAC6
expression is correlated with better survival in breast cancer.
Clin Cancer Res. 10:6962–6968. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Saji S, Kawakami M, Hayashi S, Yoshida N,
Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M,
et al: Significance of HDAC6 regulation via estrogen signaling for
cell motility and prognosis in estrogen receptor-positive breast
cancer. Oncogene. 24:4531–4539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Svotelis A, Bianco S, Madore J, Huppé G,
Nordell-Markovits A, Mes-Masson AM and Gévry N: H3K27 demethylation
by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2
determines ERα ligand dependency. EMBO J. 30:3947–3961. 2011.
View Article : Google Scholar : PubMed/NCBI
|
